Skip to main content
Neuropsychopharmacology logoLink to Neuropsychopharmacology
. 2015 Mar 13;40(5):1307. doi: 10.1038/npp.2014.338

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

Gerard Sanacora, Alan F Schatzberg
PMCID: PMC4367478  PMID: 25767082

Correction to: Neuropsychopharmacology (2015) 40, 259–267; doi:10.1038/npp.2014.261; published online 22 October 2014

On page 262 (first paragraph under ‘Ketamine's Abuse Liability: Mu Opioid Receptor Effects'), the references to lambda opioid receptors and lambda antagonists should have been to delta opioid receptors and delta antagonists. The same error appears on page 264 (second paragraph under ‘Novel Drug Development').


Articles from Neuropsychopharmacology are provided here courtesy of Nature Publishing Group

RESOURCES